Innotox
Innotox is a Botulinum Toxin Type A developed by
Medytox Korea Limited. It was approved by the
Korean Drug Administration (KDA) in 2004 and
has shown better and more consistent results
compared to traditional BTX products.
The most common side effects after injection
may include bruising at the injection site,
mild headache, dry eyes, drooping eyelids,
or slight uneven skin appearance. Most of
these effects are temporary and usually fade
and disappear over time.
Adverse effects are more likely when treating
medical conditions due to higher doses and
existing risk factors related to the illness.
In rare cases, the toxin may spread beyond
the injection area. If it reaches respiratory
muscles, it may cause breathing difficulties
or respiratory paralysis.
Duration of effects:
The treatment effects usually last for
4 to 6 months. Repeat treatment is required
after the effect wears off.
Innotox works by acting on cholinergic motor
nerve endings. It blocks calcium ion activity
and interferes with the release of acetylcholine
from motor nerves. This prevents muscle fibers
from contracting, allowing the muscles to relax
and smooth wrinkles.
Facial wrinkles are mainly caused by repetitive
facial muscle movements. Injection treatment
reduces muscle activity and weakens wrinkle
formation. It is effective for smoothing
forehead lines, frown lines, eye wrinkles,
mouth wrinkles, and nose bridge lines.
